KCSA to handle IR for BioLineRx

JERUSALEM: BioLineRx, a biopharmaceutical development company, has selected New York-based agency KCSA Strategic Communications to manage its investor relations.

JERUSALEM: BioLineRx, a biopharmaceutical development company, has selected New York-based agency KCSA Strategic Communications to manage its investor relations.

KCSA will be responsible for implementing a comprehensive IR communications campaign to build awareness of BioLineRx among the US investment community. Todd Fromer, managing partner at the agency, will lead the account.

In July, BioLineRx listed its shares on the NASDAQ Capital Market. The biopharma company develops products for central nervous system diseases, oncology, infectious diseases, cardiovascular, and autoimmune diseases.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.